Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fdaa64756184e715af6cb25ebc318917 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 |
filingDate |
1998-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f69483e451b8322cd7ec6aec11d1f8f9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3634e7d769e24d14d23aeae0bf4e7ebc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a15cd13de2ab59117b3c37d25db5dab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9cef21e00596a6c2957b06e62e1006dc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4bcc91c3fc93f1d55a00410adc4b646d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb3d445c3db74e07355f98cedb479a77 |
publicationDate |
2000-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-0989861-A1 |
titleOfInvention |
Immunogenic compositions for induction of anti-tumor immunity |
abstract |
The invention relates to the use of an immunogen selected from the group consisting of: (i) a monoclonal antibody (mAb) to a tumor-associated antigen (TAA); (ii) a fragment of a mAb of (i); (iii) a peptide based on a complementarity-determining region (CDR) of the heavy or light chain of said mAb of (i), which peptide is capable of eliciting antibodies to said TAA; and (iv) a DNA molecule coding for the variable (V) region of said mAb of (i) in a suitable gene delivery vehicle, for the preparation of a pharmaceutical composition useful for induction of anti-tumor immunity in mammals, for activing an enhanced immune response to a TAA molecule in mammals, and/or for induction of immune responses to mutated and wild-type forms of a TAA in mammals. The use of anti-p53 mAbs and novel peptides based on the CDR2 and CDR3 of the heavy chains and CDR3 of the light chains of different anti-p53 mAbs are disclosed. |
priorityDate |
1997-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |